Valion Bio Closes $7.7M Financing with 3i, Appoints Two New Directors
VBIO sits 17% above its 52-week low of $2.79.
Summary
Valion Bio closed a $7.7M financing with 3i, LP, but only $1.5M is new cash; the rest covers overdue payments and fees. Two new directors were also appointed.
Key Events · Financing and Capital Events · VBIO
-
$7.7M Financing Closed with 3i
Valion Bio issued 100 Series B Preferred Shares, 7,637 Series C Preferred Shares, and warrants for 1,057,046 common shares at $3.62 exercise price to 3i, LP for a $7,737,000 purchase price.
-
Only $1.5M New Cash Received
Of the $7.7M purchase price, $6,137,000 was retained by 3i to satisfy overdue cash true-up payments, $100,000 for legal fees, and only $1,500,000 was paid to the Company in cash.
-
Warrant Overhang Added
The deal includes Series B Warrants for 3,077 shares and Series C Warrants for 1,053,969 shares at $3.62 per share, adding potential future dilution.
-
Two New Directors Appointed
Jared Malbin (COO of Lucid Capital Markets) and Thomas Jensen (CEO of Allarity Therapeutics) were appointed to the Board effective August 27, 2026.
Analysis · VBIO · Life Sciences
A $7.7 million financing with activist investor 3i, LP has closed, but only $1.5 million of that is new cash — $6.1 million was retained by 3i to satisfy overdue true-up payments and $100,000 covered legal fees. The deal also includes warrants for over 1 million shares at $3.62, adding potential dilution. Simultaneously, the company appointed Jared Malbin and Thomas Jensen to its board, strengthening governance after the CEO's termination. This financing provides critical runway for a company with only $2.1 million in cash and going concern doubt, but the structure heavily favors 3i and leaves limited new capital for operations.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $2.79 to $80.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.